Ultra-low fouling and anti-infective and anti-thrombotic nitric oxide releasing intravascular catheters
Ended Project Grant Awarded Last action
- Award ID
- R42HL149595
- Recipient
-
Nytricx, Inc. UEI GF9DV4ACBHH8
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,995,432
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Georgia, USA
Award details come from USAspending.gov.
Description
- Abstract
- Nytricx is developing a new class of nitric oxide (no)-releasing intravascular medical catheters to combat infection and THROMBOSIS associated with indwelling vascular catheters. No gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx no-releasing technology to the catheter surfaces via a polymer matrix, mimics the natural release by cells to prevent infection and THROMBOSIS. The nytricx technology is designed to combine anti-infective and anti-thrombotic properties of nitric oxide (no) release at the internal and external catheter interfaces, which may be an extremely effective means to prolong catheter life, decrease chronic infection, and blood clotting (THROMBOSIS) associated with intravascular catheters. The combination of a novel topcoats with no gas release from the base silicone polymer is unique, especially considering that the no donor itself stays embedded in the polymer with only the no gas escaping to affect the external and internal catheter environments. The topcoat also affects biofilm formation which is also a chronic problem associated with catheter infections preventing effective antibiotic therapy. Nytricx no-releasing technology represents a disruptive innovation that will result in saving patients' lives and cutting medical costs, especially those related to hospital acquired blood steam infections and THROMBOSIS, associated with intravascular catheters.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $121,338 | |
| Amendment | $875,855 | |
| Amendment | $50,000 | |
| Amendment | $50,000 | |
| Amendment | $106,358 | |
| Amendment | $106,358 | |
| Amendment | $106,358 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,193,055 | |
| Amendment | $1,193,055 | |
| Original award | $1,193,055 |
Show all 14
Quick answers
Who received award R42HL149595?
R42HL149595 was awarded to Nytricx, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on May 1, 2020.
How much is award R42HL149595 worth?
$4,995,432 has been obligated on R42HL149595.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award